MCKESSON CORPORATION & ITS AFFILIATE U.S. ONCOLOGY for MCKESSON CORPORATION & ITS AFFILIATE U.S. ONCOLOGY
A later version of this report replaces this one, so LegiList's totals use the current version instead. This page shows this version exactly as filed.
Versions of this report
Every filing the register holds for this firm, client and period, oldest first. The most recent one is the version LegiList counts.
| Filing | Filed | Amount | Counted |
|---|---|---|---|
| 3rd Quarter - Report (this page) | Oct 20, 2020 | $200,000 | Replaced |
| 3rd Quarter - Amendment | Nov 24, 2020 | $230,000 | Yes |
What was lobbied
5 issue areas, each in the filer's own words, with who lobbied on it and where.
Tariff (miscellaneous tariff bills) TAR
USTR Section 301 proposed tariffs.
| Lobbyist | Covered position, as disclosed |
|---|---|
| JOSHUA C BABB | — |
| PETER SLONE | — |
Taxation/Internal Revenue Code TAX
H.R./S.1: Tax Cuts and Jobs Act.
| Lobbyist | Covered position, as disclosed |
|---|---|
| JOSHUA C BABB | — |
| PETER SLONE | — |
Health Issues HCR
Implementation of Comprehensive Addiction and Recovery Act (CARA) PL 114-198 and education regarding opioid treatment and prevention; Implementation of 21st Century Cures (H.R. 34), advocacy related to healthcare technology and innovation issues; E-Rx (H.R.3528), advocacy related to electronic prescriptions of medications; Implementation of FY'2018 NDAA provision related to e-Commerce portals; education about potential improvements to Prescription Drug Monitoring Programs; H.R. 6 Substance Use- Disorder Prevention that Promotes Opioid Recovery and Treatment (SUPPORT) for Patients and Communities Act; Education about improvements to Prescription Drug Monitoring programs that would promote greater efficiency and utility at the pharmacy and other issues related to opioid abuse.
| Lobbyist | Covered position, as disclosed |
|---|---|
| JOSHUA C BABB | — |
| PETER SLONE | — |
Medicare/Medicaid MMM
Physician and pharmacy reimbursement issues;Legislation to amend Part B of title XVII of the Social Security Act to exclude customary prompt pay discounts from manufacturers to wholesalers from the average sales price for drugs and biological under Medicare; Site neutral payment reforms;Issues related to physician reimbursement for Part B drugs;Support for increased transparency and accountability in Medicare's local determination process (S.794/H.R. 3635); Issues as they relate to opioid abuse policy; General Medicare/Medicaid Issues; Issues related to reimbursement for radiation therapy services; 340B, education related to need for sensible reforms in 340B that protect indigent beneficiaries and community oncology practices; Pandemic and All Hazards Preparedness Act reauthorization; issues related to step therapy policies in Medicare Advantage plans; Medicare physician payment; Issues related to an alternative payment model for radiation oncology services; Issues related to the Center for Medicare and Medicaid Innovation; Issues related to the ANPRM International Pricing Index Model for Medicare Part B Drugs; issues related to the Oncology Care First model.
| Lobbyist | Covered position, as disclosed |
|---|---|
| JOSHUA C BABB | — |
| THOMAS BORCK | — |
| BEN JONES | — |
| LISA LANGENDERFER | — |
| PETER SLONE | — |
Pharmacy PHA
Pharmacy issues, prescription drug supply chain issues, drug shortages, prescription drug abuse and diversion; support for legislation to preserve patient access to oral oncolytics dispensed by community-based cancer clinics (H.R. 1316); DIR (H.R. 1038), advocacy related to ending retroactive direct and indirect renumeration fees levied on pharmacists; Provider status (H.R. 592), advocacy related to recognizing and reimbursing pharmacists for providing appropriate medical services; H.R. 6688, The Analyzing and Leveraging Existing Rx Transactions (ALERT) Act.
| Lobbyist | Covered position, as disclosed |
|---|---|
| JOSHUA C BABB | — |
| THOMAS BORCK | — |
| BEN JONES | — |
| LISA LANGENDERFER | — |
| PETER SLONE | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.